

# Hypertension - Pipeline Review, H2 2019

<https://marketpublishers.com/r/H76449E77201EN.html>

Date: December 2019

Pages: 699

Price: US\$ 2,500.00 (Single User License)

ID: H76449E77201EN

## Abstracts

Hypertension - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H2 2019, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved

in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 2, 37, 40, 27, 1, 80, 24 and 5 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 18 and 8 molecules, respectively.

Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

Introduction

Hypertension - Overview

Hypertension - Therapeutics Development

Hypertension - Therapeutics Assessment

Hypertension - Companies Involved in Therapeutics Development

Hypertension - Drug Profiles

Hypertension - Dormant Projects

Hypertension - Discontinued Products

Hypertension - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Hypertension, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Products under Development by Companies, H2 2019 (Contd..11), H2 2019

Products under Development by Companies, H2 2019 (Contd..12), H2 2019

Products under Development by Companies, H2 2019 (Contd..13), H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019  
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Hypertension - Pipeline by A1M Pharma AB, H2 2019  
Hypertension - Pipeline by Aadi Bioscience Inc, H2 2019  
Hypertension - Pipeline by Abivax SA, H2 2019  
Hypertension - Pipeline by Acceleron Pharma Inc, H2 2019  
Hypertension - Pipeline by Actelion Pharmaceuticals Ltd, H2 2019  
Hypertension - Pipeline by Adhera Therapeutics, H2 2019  
Hypertension - Pipeline by Aerogen Ltd, H2 2019  
Hypertension - Pipeline by Aggamin LLC, H2 2019  
Hypertension - Pipeline by AI Therapeutics, H2 2019  
Hypertension - Pipeline by Ajanta Pharma Ltd, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Hypertension, H2 2019  
Number of Products under Development by Companies, H2 2019  
Number of Products under Development by Universities/Institutes, H2 2019  
Number of Products by Top 10 Targets, H2 2019  
Number of Products by Stage and Top 10 Targets, H2 2019  
Number of Products by Top 10 Mechanism of Actions, H2 2019  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019  
Number of Products by Top 10 Routes of Administration, H2 2019  
Number of Products by Stage and Top 10 Routes of Administration, H2 2019  
Number of Products by Top 10 Molecule Types, H2 2019  
Number of Products by Stage and Top 10 Molecule Types, H2 2019

### COMPANIES MENTIONED

A1M Pharma AB  
Aadi Bioscience Inc  
Abivax SA  
Accelaron Pharma Inc  
Actelion Pharmaceuticals Ltd  
Adhera Therapeutics  
Aerogen Ltd  
Aggamin LLC  
AI Therapeutics  
Ajanta Pharma Ltd  
Alnylam Pharmaceuticals Inc  
Altavant Sciences Inc  
AMAG Pharmaceuticals Inc  
AnGes Inc  
AOBiome LLC  
Apaxen  
Apollo Therapeutics LLC  
APT Therapeutics Inc  
Aqualung Therapeutics Corp  
Attgeno AB  
ATXA Therapeutics Ltd



AVEO Oncology Inc  
Bayer AG  
Beijing Wehand-Bio Pharmaceutical Co Ltd  
Bial - Portela & Ca SA  
Biogen Inc  
BioRestorative Therapies Inc  
BioStem Technologies Inc  
Boehringer Ingelheim International GmbH  
Boryung Pharmaceutical Co Ltd  
Bristol-Myers Squibb Co  
C4X Discovery Holdings Plc  
Camurus AB  
Capricor Therapeutics Inc  
CardioPharma Inc  
Cellmid Ltd  
Celsion Corp  
Celtaxsys Inc  
Chiesi Farmaceutici SpA  
Chong Kun Dang Pharmaceutical Corp  
Chugai Pharmaceutical Co Ltd  
CinCor Pharma Inc  
CJ HealthCare Corp  
Complexa Inc  
CSPC Pharmaceutical Group Ltd  
Cumberland Pharmaceuticals Inc  
D. Western Therapeutics Institute Inc  
Daewon Pharmaceutical Co Ltd  
Daewoong Co Ltd  
Daewoong Pharmaceutical Co Ltd  
Daiichi Sankyo Co Ltd  
Denovo Biopharma LLC  
Eldrug SA  
Eli Lilly and Co  
Elyson Pharmaceutical Co Ltd  
Esperion Therapeutics Inc  
Excubio Pharmaceuticals Inc  
FunPep Co Ltd  
Galectin Therapeutics Inc  
Gemphire Therapeutics Inc

GenKyoTex SA  
GenThera Inc  
GEXVal Inc  
Gilead Sciences Inc  
Gmax Biopharm Ltd  
Gossamer Bio Inc  
Guangzhou Magpie Pharmaceutical Co Ltd  
H. Lundbeck AS  
Hanmi Pharmaceuticals Co Ltd  
Hetero Labs Ltd  
Himuka AM Pharma Corp  
Idorsia Pharmaceutical Ltd  
Innolife Co Ltd  
Innopharmax Inc  
Insmed Inc  
Insys Therapeutics Inc  
Inven2 AS  
INVENT Pharmaceuticals Inc  
Ionis Pharmaceuticals Inc  
Japan Tobacco Inc  
Jeil Pharmaceutical Co Ltd  
Jiangsu Hengrui Medicine Co Ltd  
KBP BioSciences Co Ltd  
Kyowa Kirin Co Ltd  
Kyung Dong Co Ltd  
Larix Bioscience LLC  
Lee's Pharmaceutical Holdings Ltd  
Les Laboratoires Servier SAS  
LG Chem Ltd  
Liaoning Haiwang Biotechnoloty Co Ltd  
LinXis BV  
Liquidia Technologies Inc  
LTT Bio-Pharma Co Ltd  
Martin Pharmaceuticals Inc  
Merck & Co Inc  
Mezzion Pharma Co Ltd  
Mifcare  
Morphogen-IX Ltd  
Nippon Shinyaku Co Ltd

Nissan Chemical Corp  
Noorik Biopharmaceuticals AG  
Northern Therapeutics Inc  
Novartis AG  
NuSirt Biopharma Inc  
Omeros Corp  
Orion Corp  
Overseas Pharmaceuticals Ltd  
Panorama Research Inc  
Park Active Molecules  
Pharming Group NV  
Pharmosa Biopharm Inc  
PhaseBio Pharmaceuticals Inc  
Proteo Inc  
Pulmokine Inc  
Q BioMed Inc  
QR Pharmaceuticals Ltd  
Quantum Genomics SA  
Radikal Therapeutics Inc  
Reata Pharmaceuticals Inc  
Relief Therapeutics Holding AG  
Relypsa Inc  
Renova Therapeutics Inc  
Respira Therapeutics Inc  
Resverlogix Corp  
Reviva Pharmaceuticals Inc  
Ridge Therapeutics LLC  
RMJ Holdings LLC  
Samik Pharmaceutical Co Ltd  
Sanofi  
Sarfez Pharmaceuticals Inc  
Schrodinger LLC  
Scipharm SaRL  
Scohia Pharma Inc  
Shanghai Pharmaceutical Co Ltd  
Shanghai Xinyi Pharmaceutical Co Ltd  
Shenzhen Salubris Pharmaceuticals Co Ltd  
SJT Molecular Research SL  
Sorrento Therapeutics Inc

Sosei Heptares  
SteadyMed Therapeutics Inc  
Stocosil Inc  
Suda Pharmaceuticals Ltd  
Sulfateq BV  
Sun Pharma Advanced Research Company Ltd  
Synokem Pharmaceuticals Ltd  
Takeda Pharmaceutical Co Ltd  
Target Medicals LLC  
Theracos Inc  
Theragene Pharmaceuticals Inc  
Theravance Biopharma Inc  
Topadur Pharma AG  
Translate Bio Inc  
Tritech Biopharmaceuticals Co Ltd  
United Therapeutics Corp  
Vascular BioSciences  
VasThera Research Institute  
Vectus Biosystems Ltd  
Velocity Pharmaceutical Development LLC  
VG Life Sciences Inc  
Vivus Inc  
Windtree Therapeutics Inc  
XuanZhu Pharma Co Ltd  
Yuhan Corp  
Zhejiang Conba Pharmaceutical Co Ltd

## I would like to order

Product name: Hypertension - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/H76449E77201EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H76449E77201EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970